Veterinary

Trupanion Reconvenes Council on Animal Health; Provides Data-Driven Update on ‘Mystery’ Canine Respiratory Illness

Retrieved on: 
Tuesday, February 13, 2024
Research, Professional Services, Payments, Consumer, Technology, Infectious Diseases, Health Insurance, Science, Veterinary, Insurance, Health, Pets, Pet, Multimedia, Dog, COVID-19, Cat, Infection, MRCVS, Public, Vaccine

Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, reconvened world-renowned animal health and infectious disease authorities to continue the investigation into the reported uptick of on canine respiratory illness.

Key Points: 
  • Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, reconvened world-renowned animal health and infectious disease authorities to continue the investigation into the reported uptick of on canine respiratory illness.
  • Dr. Steve Weinrauch, BVMS, MRCVS, Chief Veterinary & Product Officer of Trupanion, noted, “We’re proud to be at the forefront of the intersection between pet and public health.
  • As discussed by the panel, this could be attributed to respiratory vaccine compliance, increased pet owner awareness and sensitivity to respiratory signs, or pure coincidence.
  • Trupanion's Chief Veterinary and Product Officer, Dr. Steve Weinrauch, is available to share canine respiratory illness related insights or to provide context regarding pet health data as it relates to the extensive Trupanion database.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, Other Health, Technology, Stem Cells, Pharmaceutical, Surgery, Medical Devices, Genetics, Clinical Trials, Biotechnology, Science, Software, Veterinary, Other Science, Research, Health, Meiji University, Embryology, Cell, Doctor of Philosophy, Coagulation, Inflammation, Quality of life, Pelvic floor dysfunction, Transgene, Transplant, Genome, Patient, Gene, Kidney, Mortality, Tissue, Vaccine

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Adtalem Global Education Names Scott Liles as the New Medical and Veterinary President

Retrieved on: 
Tuesday, February 13, 2024
Veterinary, Pets, Health Insurance, Other Education, Continuing, General Health, University, Consumer, Health, Education, U.N, Financial services, Doctor of Philosophy, Medicine, Nationwide, Growth, Adtalem Global Education, AUC, Veterinary medicine, MBA, RUSM, Accenture, London Business School, American University, McKinsey & Company, ACAMS, Economics, Texas A&M University, ATGE, Management

Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and the nation’s largest healthcare educator1, has appointed Scott Liles as president, Adtalem medical and veterinary, effective April 1.

Key Points: 
  • Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and the nation’s largest healthcare educator1, has appointed Scott Liles as president, Adtalem medical and veterinary, effective April 1.
  • In his new role, Liles will have principal responsibility for the academic, operational and financial outcomes of the Medical and Veterinary reporting segment.
  • His strong business acumen and expertise in leading global organizations make him a fantastic addition to the Adtalem leadership team,” said Steve Beard, president and CEO, Adtalem Global Education.
  • “It’s an honor to rejoin the Adtalem family and be part of the solution to fulfilling the needs of the healthcare workforce while impacting local and global communities,” said Scott Liles, president, Adtalem medical and veterinary.

Zoetis Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 13, 2024
Veterinary, Health, Sarolaner, Acquisition, International, Livestock, Tick, Artificial intelligence, Poultry, Investment, Pig, Pain, Animal, Growth, Dog, Dermatology, Coccidioides immitis, Vaccine, OA, Virus, Webcast, Cat, Osteoarthritis, Inc., Pharmaceutical industry

(NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

Key Points: 
  • (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.
  • The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational1 basis.
  • In the fourth quarter of 2023:
    Revenue in the U.S. segment was $1.2 billion, an increase of 9% compared with the fourth quarter of 2022.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts.

Swine Vaccines Industry Research Report 2024: Market Anticipated to Surge Amid Technological Innovations and Rising Global Pork Consumption - Long-term Forecasts to 2028 and 2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 9, 2024
Pharmaceutical, Health, Veterinary, Vaccination, Acquisition, Growth, Infection, Climate, Vaccine, Pharmacy, Safety, DNA, Incidence, Intelligence, Pseudorabies, Pig, CML, Disease

The "Swine Vaccines Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Swine Vaccines Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global swine vaccines market has grown strongly in recent years.
  • The global swine vaccines market is expected to see strong growth in the next few years.
  • The escalating incidence of diseases in swine is anticipated to drive growth in the swine vaccine market.

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

Retrieved on: 
Wednesday, February 7, 2024
Veterinary, Health, EPS, Growth, Knowledge, GAAP, Adjustment, Animal Health, Investment, Corporation, Poultry, Vaccine, Acquisition, PAHC, Webcast

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024.
  • Jack continued, “We expect continuing growth in our Animal Health business in the second half of the year.
  • Glenn brings over 30 years of experience in commercial and financial leadership roles, including a wealth of knowledge in the animal health industry.
  • Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.

BARK Reports Third Quarter Fiscal Year 2024 Results

Retrieved on: 
Wednesday, February 7, 2024
Online Retail, Retail, Health, Consumer, Specialty, Pets, Veterinary, Net, Advertising, G&A, Note, Uncertainty, Public expenditure, BARK, Adjustment, Marketing, Commerce, Economics, Acquisition, Bookkeeping

We expect to be Adjusted EBITDA positive in the fiscal fourth quarter and have solid visibility into bottom line improvements in fiscal 2025."

Key Points: 
  • We expect to be Adjusted EBITDA positive in the fiscal fourth quarter and have solid visibility into bottom line improvements in fiscal 2025."
  • The Company is increasing the low-end of its revenue range due to its stronger-than-expected third quarter results.
  • For the fiscal fourth quarter 2024, the Company expects:
    Total revenue of $118.4 to $123.8 million.
  • A conference call to discuss the Company's fiscal third quarter 2024 results will be held today, February 7, 2024, at 4:30 p.m.

Global Veterinary Rapid Test Kits Outlook Report 2023-2028: Market to Surge at 8.53% CAGR, Propelled by Advancements in Point of Care Testing and Expanding Pet Ownership - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 7, 2024
Health, Veterinary, Pets, Consumer, Growth, Human, Environment, Prevalence, Dog, Zoonosis, Ecosystem, Investment, Point-of-care testing, Animal, Pithing, Diabetes, Laboratory, POCT, Infection, Cat, Allergy, Idexx Laboratories, Cancer, Pet, Livestock

The "Veterinary Rapid Test Kits Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Rapid Test Kits Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The veterinary rapid test kits market is exhibiting considerable growth, with projections to expand at a compelling CAGR of 8.53% between 2022 and 2028.
  • The veterinary rapid test kits market is a testament to the advancing frontiers in animal health diagnostics.
  • Rapidly soaring pet ownership rates are catalyzing the demand for veterinary rapid test kits.

Woof Gang Bakery & Grooming Paints Canada Pink With Opening of First Store in Ontario

Retrieved on: 
Wednesday, February 7, 2024
Veterinary, Other Retail, Pets, Health, Entrepreneur, Specialty, Consumer, Retail, Growth, Science, Dog, Love, Great, Greater Toronto Area, Tim Hortons, Pet, Drug

Woof Gang Bakery & Grooming , the renowned pet care brand, is thrilled to announce the official opening of its first Canadian store in Oakville, Ontario.

Key Points: 
  • Woof Gang Bakery & Grooming , the renowned pet care brand, is thrilled to announce the official opening of its first Canadian store in Oakville, Ontario.
  • The Oakville location is the first step in a larger plan by Woof Gang to "paint Canada pink."
  • Just as Tim Hortons franchisees across Canada are celebrated for their profound connection and dedication to their local communities, Woof Gang Bakery & Grooming embodies a similar spirit of commitment and passion.
  • To learn more about Woof Gang Bakery & Grooming, visit www.woofgangbakery.com .

Zoetis Declares Second Quarter 2024 Dividend

Retrieved on: 
Tuesday, February 6, 2024
Veterinary, Research, Pets, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

Key Points: 

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the second quarter of 2024. The dividend will be paid on Tuesday, June 4, 2024, to all holders of record of the Company’s common stock as of the close of business on Friday, April 19, 2024.